Close Menu

stock offering

On Thursday, Predictive Oncology closed another direct offering initiated earlier in the week, raising $2.2 million.

The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million.

The precision oncology company plans to use the proceeds to advance drugs in its pipeline, improve its RADR platform, and acquire new therapeutic assets.

The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.

The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.